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Key points: 
1. There is no high quality comparative effectiveness research for surgery versus 
pharmacological management or for different surgical techniques.  
2. High quality evidence (randomised controlled trials) is required to inform routine 
decision making for patients with TN and their consultants. 
3. The design and conduct of surgery trials using the standard design has numerous 
challenges (patient preferences, clinician preferences, clinically meaningful outcome 
measures, learning curves for surgical techniques, irreversibility of results)  
4. The µcohort multiple RCT¶ design is an innovative alternative design that provides 
both long term observational data and a facility for quick and efficient conduct of 
multiple trials. Unlike standard trials, patient information and consent replicate that 
found in routine healthcare wherever possible. 
5. Embedding multiple trials within a cohort of patients with a diagnosis of TN would 
enable the quick and efficient identification and recruitment of patients to trials of a 
variety of interventions, and help provide the information that patients and clinicians 
require. 
 
Synopsis 
Should patients undergo a surgical intervention as soon as they receive a diagnosis of  
trigeminal neuralgia  (TN), or should they wait until pharmacological treatment fails?  
Knowing the answer to this question would help inform patient and clinician decision making. 
To answer this question, randomised controlled trials (RCTs) comparing standard medical 
pharmacological interventions with surgical treatments are needed. This article describes 
some of the challenges that have been encountered in surgical trials for TN, and provides 
some guidance for future trials in this area. One future direction for TN research is to utilise 
the LQQRYDWLYHµFRKRUWPXOWLSOH5&7GHVLJQ¶. This approach enables multiple trials to be 
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embedded within a single cohort of patients a diagnosis of TN, providing an efficient and 
effective approach to the testing of multiple interventions for TN with each other and with 
usual care. 
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Introduction ± which trials are needed? 
Unusually trigeminal neuralgia (TN), a rare disease, can be managed both medically 
(pharmacologically) and surgically, and there is some evidence of the importance of 
psychological therapies. So what trials are needed?  
1. Comparison of medical vs surgical treatments 
Surgical management can yield 100% pain relief for 70% of patients for 10 years Tatli 1 
Zakrzewska coakham 2. Medical management provides 50% pain relief but becomes 
less effective over time and as the doses is raised result in poorer tolerability Besi 3 . 
Many of these patients eventually opt for surgery but best timing of this is still unknown. 
Zakrzewska Linskey 4 Although the majority of patients remain on medical management 
until it fails Taylor 5  Di Stefano 6, there is evidence that patients prefer surgical 
management  Spatz 7et al. Zakrzewska et al Zakrzewska coakham 8reviewing 220 
patients who had posterior fossa found 73% said they would have preferred earlier 
surgery.  
There is also evidence that clinicians/ surgeons support early surgery for classical 
cases of TN and those with positive imaging Nurmikko and Eldridge 9. Others suggest 
that surgical treatments should only be offered after patients become refractory to 
medical management which is defined by Obermann as failure of two drugs Obermann 10 
10
. Di Stefano 6et al in their cohort of 200 patients on medical management suggest that 
medications remain highly effective and only 7% in their cohort needed surgery. 
However, there is no rigorous (i.e. randomised controlled trial RCT) evidence to 
support either an early or delayed surgical management compared to 
pharmacological management of TN.  The recent Cochrane systematic review on 
neurosurgical interventions in TN identified just 11 RCTs involving 496 patients Akram, 11 
however the majority of these trials were biased.  None of the high quality trials 
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compared different surgical techniques with each other or compared surgery with 
pharmacological management. The three high quality RCTs compared different surgical 
techniques with potentially more refined versions of the same technique Akram 11. There 
were no RCTs of microvascular decompression  MVD, (the most invasive procedure and 
only non-destructive  procedure) but with observational data which suggests that it may 
have the best long term outcomes for pain relief. Cruccu 12 
Given patient and clinician preferences and the lack of evidence to support surgery or 
pharmacological management, the most important research question for the TN 
profession is should patients undergo a surgical intervention as soon as the diagnosis 
has been made (i.e. very early in the course of the condition), or should  they wait until 
the conservative (pharmacological) treatment has failed? In other words, should they 
receive surgical treatment that provides something very close to a cure (albeit not 
necessarily permanent) cure or remain on medication? If early surgery was comparable 
to (or better than medical management) this information would impact on how patients 
viewed their options at the time of diagnosis, and provide more flexibility in the decision 
making process in the early stages. 
 
2. Comparison of the different surgical techniques  
There are an emerging number of studies comparing different techniques, however the 
interpretation of the results of these studies is hampered by differences in the outcomes 
used and the short duration of outcomes. Linskey 13 Future trials should use the same 
outcomes and also follow up patients for 5+ years. Tatli 1  
 
3. New and comparative drug trials  
Drug trials in TN are few and far between and most drugs used to date have been 
established anti-epileptics. However there is now a potential for a new drug with good 
efficacy and better tolerability to be evaluated. Phase 2 studies have been completed 
using a novel design of enriched enrolment randomized withdrawal (EERW) design in 
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which patients are initially screened, and then all are put on the active drug for a set 
period Zakrzewska 14.  After this period only those considered to have been responders 
are allocated to the randomised   part of the trial where the active drug is compared to a 
placebo. In this design there is a set time for the trial but non responders are encouraged 
to drop out. Moore et al  Moore 2015 15have done a systematic review of all the pain 
trials using the EERW trial design and suggest that these can play an important role if 
correctly designed but may be difficult to compare outcomes with classical trials. 
Comparisons of different drugs are also required and whether single of multiple drugs 
should be used Cruccu 12 . 
 
4. Addition of psychological therapies .  
TN has considerable impact on quality of life and patients live in fear of a recurrence of 
their pain Allsop 16 . One small study (n= 15) has shown that spontaneous pain as 
opposed to pain evoked by a trigger could be driven by emotional factors Moisset 17  
There is anecdotal evidence from surgeons and patients that patients are reluctant to 
touch their faces after surgical treatments in case they trigger an attack, this behaviour is 
also seen in continuation of medications post surgery especially after stereotactic 
surgery (SRS).   
In summary there are a number of research questions in the field of TN that require evidence 
from well design RCTs. This article describes a number of challenges in the design and 
conduct of trials with a particular emphasis on surgical trials for TN. It will provide some 
pointers for future trials.   
Problems with randomised controlled trials  
This section describes the problems with the design, implementation and interpretation of 
RCTs  of interventions to help patients with their health.  
1. Recruitment  
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RCTs often have difficulty recruiting sufficient numbers of patients.  Macdonald et al 18, found 
that less than a third of 114 multicentre, publicly funded UK RCTs recruited their original 
target number of patients within the time originally specified. Failure to recruit to target may 
have implications for the power and generalisability of trial results. The sample populations 
often do not contain ethnic minorities or other hard to reach groups e.g. elderly so making it 
difficult to apply to general practise. Trials of medical management in TN are all very small. 
Zakrzewska Linskey 19  
Ethical issues 
In a systematic review of the literature on barriers to participation in RCTs, Ross 20 et al  
found that concerns with information and consent were some of the major reasons why both 
patients and clinicians were unwilling to participate in trials. In routine real world health care, 
patients are rarely told of treatments that their clinicians cannot with certainty provide  nor 
are patients told their treatment will be decided by chance Buxton 21 . On the other hand, in 
clinical trials providing this type of "full" information before randomisation is regarded as an 
ethical requirement. 7KHFRQVHTXHQFHRIWKLV³IXOO´LQIRUPDWLRQLVWKDWSatients worry about 
the uncertainty of treatment outcome especially if there is the possibility that they may be 
allocated to placebo. It is acknowledged that for clinicians there is a potential conflict of 
interest between what is good for the current patient and what is good for future patients 
Donnellan 22. These issues are nicely demonstrated in the anecdote in box 1. 
Box 1 here  
In a recent phase 2 trial patients were reluctant to be recruited as they had got reasonable 
control and tolerability and were concerned that the new drug for TN would upset this 
balance (currently unpublished ). Moreover, in general practice patients are often given less 
information about their treatments than that currently required by some ethics committees 
who are asked to review intervention trials. 
2. Patient preferences 
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Standard "open" (unblinded) pragmatic trials often compare an intervention with treatment as 
usual. Where the "standard care" on offer is available outside the trial, however, the only 
incentive for the patient to participate (apart from altruism) is to receive the new intervention. 
If a patient is allocated to treatment as usual, he or she may withdraw from the trial (attrition 
bias) or exhibit disappointment bias when reporting outcomes. Cook 23  3DWLHQW¶VFRPSOLDQFH
with their allocated intervention may vary depending on whether they receive the treatment 
of choice or not and more patients may drop out of trials if they allocated to treatment as 
usual. Patients with rare diseases are more reluctant to take part in trials for this reason rare 
diseases 24  There may therefore be a treatment effect, which results from patient 
preferences and not from therapeutic efficacy Torgerson 25. This is a major problem in TN 
were destructive treatments give very different results from non destructive methods or if 
compared to medical therapies. As surgery is irreversible patients may prefer to delay this 
yet when asked specifically about timing of MVD the majority in retrospect said they would 
have wanted surgery earlier Zak coakham 8.  
3. Treatment comparisons 
For conditions with many potential treatment options, there are often multiple trials 
conducted, with each potential treatment being trialled, one at a time, in different populations 
by different research teams, often with heterogeneous outcomes and heterogeneous trial 
populations. Thus when treatments need to be compared, they can only be done by indirect 
methods. The effectiveness of treatments A versus C can be difficult to evaluate if the only 
trials of treatments are A versus B and B versus C exist. Indirect comparisons²where two 
interventions are compared through their relative effect versus a common comparator²can 
succeed, but sometimes result in significant discrepancies compared with the results of head 
to head randomised trials. Song 262003. Many competing interventions have thus not been 
compared or have been compared inaccurately which is a waste of valuable information and 
money. This is a major problem in TN where there are no RCTs of MVD and the RCTs that 
have been done compare techniques and use varying outcome measures at varying time 
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points. It has therefore been very difficult to compare not just surgical trials but medical ones 
for the same condition. 
4. Diagnosis  
An essential of all trials is an accurate description of the participants using evidence based 
diagnostic criteria as this will enable clinicians to determine if the patients in the trial are 
representative of their patients.  TN was  considered to have very clear diagnostic criteria but 
it is now emerging that there are several variants and the nomenclature has become 
confusing with terms such as type 1 and 2  TN or TN with concomitant pain. Burchiel 27  
anon 28 . There has also been a group of conditions known as the trigeminal autonomic 
cephalalgias which include four different conditions. Two of them SUNCT short unilateral 
neuralgiform headache  with conjunctival redness tearing and SUNA s short unilateral 
neuralgiform headache  with any autonomic symptom may in fact be yet other variants of TN 
lambru 29 .   
TN and its variants are unusual in that the pain is episodic and there are unpredictable 
remissions and relapses which makes it even harder to be sure that the end result is due to 
the intervention rather than the natural history of the disorder.    
5. Timing  
 
New medications undergo a specific standardised pathway in order to become registered, 
but this is not the case for surgical interventions.  A surgical intervention passes through 
many phases of innovation and refining and has a tipping point at which the intervention is 
no longer an innovation but a routine procedure. The tipping point (when equipoise is lost) is 
extremely variable and cannot be predicted thus making the accurate timing of RCTs difficult  
.  Barkun 30 This has generated what has become known as Buxton's law: 'It is always too 
early [for rigorous evaluation] until suddenly it's too late'.Buxton 21   
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Thus the newest intervention for TN, stereotactic radiosurgery (SRS) was first assessed in 
an exploratory trial to determine its efficacy and this was done in those patients who would 
benefit most and by surgeons who had the freedom to develop and refine the intervention.  
In 2001 a RCT by Flickinger 31 et al of this procedure in a multicenter trial showed that one 
rather than two isocentre were sufficient to provide pain relief without sensory loss, one of 
the first refining studies. This could have been followed by a pragmatic trial which included a 
very broad population and surgeons with a range of expertise so it represented most closely 
what occurs in general practice. This approach would have provided information on both the 
short and long term outcomes of SRS and could have addressed cost effectiveness and 
quality of life questions if outcomes had been assessed independently. Cook 23 This would 
have then enabled a standard to be set against which audits could be carried out.   
Schnurman and Kondziolka 32,33 a b have suggested an alternative approach to this problem  
see Box 2  
 
 Box 2 here  
Schnurman 33 and Kondziolka  b  then applied this to a series of surgical procedures 
including SRS  for TN. they found  for this procedure an equal number of initial studies ,16 
with 1250 patients and 16 cohort studies and therefore estimated that the year to PAS was 
10 years , occurring in 2002-3 and years to objective efficacy i.e when accepted by the 
surgical community was 10-11 years. In comparison endovascular coiling of aneurysms took 
only 5 years to objective efficacy. These results are also influenced by accessibility and 
approval of the equipment, the rarity of the disease and the ease with which an RCT can be 
done. The authors conclude that SRS for TN could be evaluated through an RCT.   
 
6. Funding  
 
Funding is often lacking and estimates of costs of the studies can be difficult to predict due 
to the multiplicity of factors involved, estimates becomes more complicated if the trials are 
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multicentred 27. Snowdon 34 Commercial influences often also come into play and may affect 
VXUJHRQV¶LQYROYHPHQW7KHHTXLSPHQWIRUSRS is very expensive and in cost evaluations, 
which also take into account quality ±adjusted life years, SRS is the most expensive 
procedure of all surgical approaches.  Sivakanthan 35  
 
7. Choice of comparators  
 
There are many types of comparator available, but not all comparators are suitable for all 
types of surgery.  Many trials compare surgical intervention to watchful waiting or medical 
treatment and this can be a satisfactory method for chronic conditions. When comparing 
surgical procedures complications may be very different for the two interventions and this 
can affect both patient preference and blinding of outcomes e.g. ablative procedures are 
likely to result in sensory loss whereas decompression of the trigeminal nerve is highly 
unlikely to lead to sensory loss but can result in hearing loss. When the comparator is a 
different surgical technique then the same surgeon may be performing both interventions. 
He/she may be skilled in both but it is equally likely that there is a differential expertise 
between procedures. This then calls for a different approach that takes into account surgical 
expertise 12 .  Devereaux 36However, using expert surgeons may then result in an inability to 
generalise to all neuro surgeons.  
 
8. Surgeons' equipoise 
 
Equipoise means that there is uncertainty regarding whether the trial treatment will be more 
beneficial to people than the comparator. Individual surgeons often have preferences for one 
intervention over another and thus may not be willing to take part in a clinical trial. Career 
surgeons are selected for traits that include comfort with making important clinical decisions 
quickly with incomplete information. This quality, required for decisive action during 
operations, may make it difficult for them to be consciously uncertain which of two 
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treatments is better. Equipoise as to whether a treatment is effective or not is required in the 
scientific medical community but is not required from individual surgeons unless they have to 
perform two different types of surgical intervention in the trial. This can be a problem in 
neurosurgical interventions in TN as some procedures are destructive whereas others aim to 
preserve sensory function and so surgeons may be reluctant to randomise patients to 
ablative procedures which they may consider using only in those patients who are not 
medically fit for major surgery.  
 
9. Interventions 
 
In pharmacological trials the main intervention in most cases is the drug alone, however, 
surgical interventions are highly complex and include the procedure itself, the surgeon, the 
surgical team and pre and post operative care . 9 15 Cook 23, Ergina 37 
All surgical interventions have two learning curves, both of which are variable. The first is 
perfecting the surgical techniques and the second is the personal learning curve of the 
surgeon. This has been well illustrated when looking at the drop in mortality and 
complication rates of MVD  for TN over the years, mortality was over 1% and now is around 
0.2-0.4%.  Zakrzewska 2002 38 
10. Blinding  
 
Although it is considered important that both patients and health care professionals  are 
blinded to ensure that exaggerated estimates of treatment are not reported.it can lead to 
patients  being unsure of what is the  required outcome and opting for an intermediate 
outcome.Day 39  However this is much more difficult to do in non pharmacological trials then 
pharmacological trials. Boutron 40 In a review of 110 RCTs evaluating treatment of 
pharmacological and non pharmacological interventions in patients with hip or knee 
osteoarthritis it was showed that blinding was more difficult to achieve and unblinding 
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occurred more frequently in non pharmacological intervention studies. Blinding of surgical 
procedures of patients/care providers is possible if the methods to blind are common. These 
include   treatments that have the same physical characteristics and the same route of 
administration, surgical interventions that leave similar scars and post operative care e.g 
number of isocentres for delivery of radiation to the trigeminal nerve but difficult to do when a 
using a frame or not for neuronavigation for delivery of radiofrequency thermocoagulation Xu 
41
,   Blinding is improved if surgeons who performed the operation have no further contact 
with the patients. In studies where treatments are radically different e.g surgical versus drug 
therapy or where control treatments are usual care or waiting list, then blinding of one group 
becomes impossible. In some trials it may be easy to blind the patient to the procedure but 
the subsequent clinical outcomes could result in unblinding e.g different doses of radiation 
will lead to different complications. There is considerable evidence to show that unblinded 
outcomes assessment is associated with significantly larger treatment effects than blinded 
outcomes assessment. Poolman 2007 42 . When it is suspected that blinding may be 
problematical it is useful to perform an assessment e.g ask the patients which treatment they 
think they were given, as to whether the blinding was successful but current methods to do 
this assessment  are far from standardised 6. Boutron 2005 40 
 
11. Randomisation  
 
 The strength of the RCT is that by randomisation, assuming adequate concealment of group 
allocation, the distribution of any known or unknown prognostic factors at baseline arises 
purely by chance, thus randomisation is the main method that ensures that allocation bias is 
eliminated at baseline (30 Torgerson & Torgerson, 2008). . It is often possible to randomise in 
the operating theatre as shown in Erdine et al¶VWULDOof pulsed and continuous radiofrequency 
thermocoagulation for patients with TN.Erdine 43  It is essential when analysing the studies to 
ensure that the patients remain in the groups that were randomised to at the beginning of the 
study, i.e use an intention to treat analysis.  
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12. Outcome measures  
Outcomes need to be varied and include clinical, patient reported and economic both in the 
short and long term.  
Developing valid reproducible generalisable outcome measures that are then suitable for 
meta-analysis is complex and requires considerable consensus.  Boutron et al  2004  44have 
suggested a range of different types of outcome measures which are listed in Box 3  : 
BOX 3 here  
Different specialties have tried to develop some core outcome measures that will then lend 
themselves to meta-analysis and in determining the sample size of a study.  e.g pain 
Dworkin et al 2005  45, orthopaedics poolman 2009 46. Often some generic questionnaires 
are needed in order to compare to other data and the International Association for the Study 
of pain ( IASP ) have suggested a range of measures that should be used  in clinical trials of 
pain patients IMMPACT Dworkin et al 2005 45.  Measures using questionnaires  involve 
testing its test-retest reliability (reproducibility), responsiveness (ability to detect clinically 
important change), and validity Zarins 47.  The major outcome measure of surgical 
treatments for TN has been pain relief and there are very few reports of quality of life or 
other patient important outcomes Akram 48 . The Barrow Neurological Institute (BNI) scoring 
system Rogers 2000  49 (which evaluates pain intensity and numbness was first used in SRS 
and has  been adopted by several centres. However, this has not undergone psychometric 
testing and it is not clear how it is administered e.g from the medical notes or with the patient 
Sandhu 50 .   Reddy et al  have reported on the use of the BNI and a Visual Analog  Scale 
(VAS)  to determine the minimum clinically important difference in pain improvement after an 
MVD Reddy 51 2013  SRS  Reddy 2014  52but the sample sizes were small.  To overcome 
these shortcomings Lee et al 2010  53developed the Brief Pain Inventory Facial for which 
they have also estimated the minimum clinically important differences  Sandhu 2015  50and 
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have applied it pre and post surgery to a group of patients undergoing SRS Lee 2015 54and 
MVD. Bohman 2014 55 
Poolman et al 2009  46have highlighted other difficulties in using outcome instruments, these 
include cultural and linguistic considerations, physical and mental capacity of patients and 
the statistical methods used to evaluate them.   Many outcome measures are in the form of 
questionnaires which then need to be administered in an independent way to prevent the 
assessor being blinded by the researcher e.g. patient completing questionnaire in the 
presence of or help of the researchers.  
 As.  Zarins 47  point out that in many trials the outcome measures are then applied in a 
modified form which if they have not been tested invalidates them . Poolman et al 2009 
46showed in their review of outcome measures used in orthopaedic RCTs that ten trials 
(37%) used modified outcome measures and nine did not describe how the modified 
instrument was validated and retested.  Some questionnaires are generic and can be 
applied to a wide variety of conditions e.g SF36 but can have little meaning for a specific 
entity. Thus, a questionnaire that has been validated for one clinical condition is not always 
valid when applied to a different clinical entity. Pan et al 56used the SF36 in his cohort of 
patients but then did not find any other published study that used this tool and so went on to 
convert his data to the BNI as they could then compare their data. Of these the only ones 
used in TN have been the verbal rating scale of pain, Hospital Anxiety and Depression Scale 
to measure mood and the Brief Pain Inventory.   
One of the major difficulties when comparing medical against surgical trials in TN is that for 
the latter 100% pain relief is expected whereas for dug management it is set at 50% in line 
with all other pain conditions. 3DWLHQWV¶ expectations of other outcomes may be different from 
medical versus surgical treatments.    
Future approaches 
Some important requirements of future trials are listed in box 4 
17 
 
Box 4 here  
There have been various attempts to address the difficulties in designing surgical trials e.g. 
the formation of the Balliol Colloquium which reports its findings in a series of publications in 
the Lancet .  Barkun 2009 30, Ergina 37  McCulloch et al 57 have put forward their IDEAL 
model of the stages in surgical practise as shown in Box 5  
 
Box 5 here  
 
At all stages of the development of surgical practise it is possible to use RCT designs. 
Although some newer trial designs have been created to address  some of the problems 
associated with some of the challenge of recruitment and patient preferences, (patient 
preference, comprehensive cohort and randomised consent (Zelen) designs), none of these 
designs either increase the number of patients randomised and/or address the cost/ funding 
problem with standard trials.  More recently, a number of studies are embedding trials within 
cohorts. These are described below. 
 
Trials within Cohorts 
 
Cohort multiple RCT design: In 2010, Relton et al 58published their theoretical article 
GHVFULELQJWKHµFRKRUWPXOWLSOHUDQGRPLVHGFRQWUROOHGWULDO¶design. This is an innovative 
approach to the design and conduct of pragmatic or comparative effectiveness trials ± trials 
which aim to inform routine healthcare decision making Relton et al, 2010 58.  The design 
aims to address many of the problems associated with standard RCT design (as discussed 
above) which may reduce the generalizability of results, potentially introduce post 
randomisation selection bias and create a sub-optimal system for producing the information 
required for healthcare decision making.  Since the publication of the theoretical article a 
number of triallists have started using the design in the UK, Canada, and Netherlands. 
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Including both trials with usual care as comparator e.g. trials within the PICNIC cohort study 
of patients with rectal cancer (conference presentations).  Figure 1 and box 6 illustrate how 
this may be used for TN. 
 
Insert figure 1 here  
Insert box 6 here  
)LJXUH$µFRKRUWPXOWLSOH5&7¶DSSURDFKWRTN  
 
The rationale for this approach to informed consent is twofold. Firstly, as the primary motive 
for patients to enter clinical trials is not altruism, but their own direct benefit as patients.19 
Clinical trial informed consent procedures should, therefore, put the needs of the patient at 
the centre; that is, patients should not be told about treatments that they might not then 
receive, nor should they be told that their treatment will be allocated by chance. Secondly, 
WKHJUHDWHUWKHVLPLODULW\EHWZHHQSDWLHQWV¶H[SHULHQFHVLQWULDOVDQGWKHLUH[SHULHQFHVLQ
routine care, then the greater the generalisability of the trial results to patients in routine 
care.  
ThHµFRKRUWPXOWLSOH5&7¶ design will not only yield much needed data on long term 
prognosis of this condition but will allow both surgical and drug treatments and even 
adjunctive psychological treatments to all be evaluated alongside each other. It will also take 
into account patients and surgeons preferences, as it will be possible to evaluate the 
acceptability of different procedures by following up those patients who refuse the offered 
RCT.  
Research using standard RCT designs often struggles to recruit and consequently has to 
randomly allocate all patients to either group in equal proportions to maximise statistical 
power within their total sample. The large numbers of patients recruited to the cohort in the 
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cmRCT approach increases the statistical power of any RCTs and enables unequal 
randomisation. For example, a small number of patients could be randomly selected to be 
offered an expensive treatment and compared with a larger number of unselected patients. 
Unequal randomisation thus improves the efficiency of trials of high cost interventions e.g. 
SRS, compared with equal allocation. These factors strengthen the inferences in the trial, 
lower treatment costs compared with standard designs (that is, once the cohort is 
established, it potentially allows for rapid and cheap recruitment of patients for any RCT), 
and allows significant cost savings for trials of expensive treatments. Furthermore, data on 
treatment refusers provides information on the acceptability of the treatment and thus the 
generalisability of the trial results.  
RCT within a cohort design: More recently, the cmRCT design has been adapted by the 
Finnish Degenerative Meniscal Lesion Study (FIDELITY) (Sihvonen 59 et al 2013) to be able 
to incorporate one or more placebo trials of surgery within their cohort of patients with knee 
pain with meniscus injury. All patients recruited are informed that they may be offered a 
placebo intervention at some point. Sihvonen 59 et al describe this as DQµ5&7ZLWKLQ-a-
FRKRUW¶GHVLJQ 
 
Conclusion 
 
This article has described some of the challenges encountered in trials and particularly 
surgical trials for TN, and provides some guidance for future trials. One future direction for 
TN research is to used designs which embed trials with cohorts such as the innovative 
µFRKRUWPXOWLSOH5&7GHVLJQ¶7KLVDSSURDFKHQDEOHVPXOWLSOHWULDOVWREHHPEHGGHGZLWKLQD
single cohort of patients a diagnosis of TN, providing an efficient and effective approach to 
the testing of multiple interventions for TN with each other and with usual care. 
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Box 1 Problems of informed consent  ³a Canadian surgeon participating in a workshop 
on designing clinical trials. The Canadian surgeon reported explaining a trial to a potential 
participant and the fact that there was uncertainty about the best treatment. At the end of 
the discussion the surgeon asked the patient if he had any questions. ³<HV´ said the patient, 
³&DQ\RXUHIHUPHWRDVXUJHRQZKRdoes NQRZZKDWLVWKHEHVWWUHDWPHQWIRUPH"´  
(Relton, Clare (2009) A new design for pragmatic randomised controlled trials: a 'Patient Cohort' RCT of 
treatment by a homeopath for menopausal hot flushes. PhD thesis, University of Sheffield. 
http://etheses.whiterose.ac.uk/6644/ ) 
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Box 2 : The progressive scholarly acceptance (PSA ) method  
 
Aim : use publications to  chart progress from innovation to general acceptance  
Method : 
x Assumes that once there is broad acceptance that an innovation is effective the 
next series of papers focus on refining the technique. 
x The point at which there are more papers on refinement than efficacy or 
effectiveness becomes the PSA point  
x Assess authoring group to see if the procedure was being disseminated and the 
quality of the publications 
 Results :  
x Refining studies increase efficiency, decrease costs and may have a moderate 
effect on outcomes 
x Initial efficacy studies have a higher impact on patient care.  
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Box 3 Types of outcome measures  
1. ³3DWLHQW-UHSRUWHGRXWFRPHV´HJSDLQDQGGLVDELOLWLHVZKHQWKHSDWLHQW
is the outcome assessor. 
2. ³2XWFRPHVWKDWGRQRWVXSSRVHDFRQWDFWEHWZHHQSDWLHQWVDQGRXWFRPH
DVVHVVRUV´HJ05, 
3. ³2XWFRPHVWKDWVXSSRVHDFRQWDFWEHWZHHQSDWLHQWVDQGRXWFRPH
DVVHVVRUV´HJVHQVRU\WHVWLQJ 
4. ³&OLQLFDOHYHQWVDQGWKHUDSHXWLFoutcomes that will be determined by the 
LQWHUDFWLRQEHWZHHQSDWLHQWVDQGFDUHSURYLGHUV´HJOHQJWKRIKRVSLWDOL]DWLRQ
treatment failure, and repeat surgery), in which the care provider is the outcome 
assessor.  
5. ³&OLQLFDOHYHQWVDQGWKHUDSHXWLFoutcomes that will be assessed from data 
RQWKHPHGLFDOIRUP´HJGHDWKVLJQLILFDQWFRPSOLFDWLRQVKRUWWHUPORQJ
terms). 
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Box 5  Stages in IDEAL : Innovation, Development, Exploration, Assessment, and 
Long-term study   
 Stages 0 - the initial pre-human work and development 
 Stage 1 idea - first time it is used in human beings.   
 Stage 2a development - few patients recruited, few surgeons for the intervention 
 Stage 2b exploration - early exploratory phase, reports appearing  
 Stage 3 assessment -  SURFHGXUHLVSDUWRIPDQ\VXUJHRQV¶SUDFWLFHV 
 Stage 4 long term study surveillance ± databases set up, long term outcomes, 
quality assurance  
.  
 
 
 
 
Box 4 Requirements of future trials  
x Use of multi-disciplinary team and a range of different skills e.g  methodologists, 
statisticians,  database designers, patients 
x Completion of a systematic review not only of clinical material but animal studies  
x Clinical trials protocol published before the trial start so they can be modified if 
necessary  
x All trials registered on trial sites such as clinicaltrials.gov prior to their completion 
so it is transparent that the protocol outcomes are used.  
x The results published regardless of whether they are positive or negative. All 
RCTs should be reporting using the CONSORT  
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Box 6 7KHNH\IHDWXUHVRIWKHµFRKRUWPXOWLSOH5&7¶GHVLJQ 
I. All patients with a diagnosis of TN are recruited into a large observational cohort 
study, all receive treatment as usual (which may include medical or surgical 
options) 
II. Appropriate easily collected outcome measures are chosen and measured at 
regular intervals for the whole cohort ± including description of treatment as usual. 
 
For each randomised control trial in the field of TN e.g. MVD  or a new drug 
III. All patients who are eligible for the trial are identified froPWKHFRKRUW³1$´ 
IV. 8VLQJUDQGRPLVDWLRQDVHOHFWLRQRISDWLHQWV´Q$DUHidentified and then offered 
trial intervention  ³Q$´ 
V. The outcomes of those randomly selected ´Q$´DUHWKHQFRPSDUHGZLWKWKH
outcomes of those eligible patients not selected (but who were eligible to be 
selected) ³1A- nA´ 
VI. The information given to patients and the consents sought from patients are as 
similar as possible to those found in routine care. All cohort patients consent to 
provide observational data at the outset; however, consent to "try" a particular 
intervention is sought only from those offered that intervention, thus replicating the 
patient centred information and consent procedures that exist in routine health 
care, where clinicians provide patients with the information they need, at the time 
they need it.  
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